• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Haemonetics to cut 11% of workforce

Haemonetics to cut 11% of workforce

November 7, 2017 By Brad Perriello

HaemoneticsHaemonetics (NYSE:HAE) said today that it plans to cut roughly 11% of its global workforce as it looks to pare $80 million from its annual cash burn by the end of fiscal 2020.

The Braintree, Mass.-based blood management company said it plans to eliminate 350 positions by the end of its fiscal year in April. The company reported employing 3,107 workers as of April 1; a spokeswoman told MassDevice.com this morning that some of the affected positions are already open. Other cuts are in store for direct material and indirect spending, facilities and freight over the next 30 months, the company said.

“The workforce reduction will exclude certain identified critical roles in direct selling and clinical support, hourly plant workers and employees involved in critical, time-bound projects, as the company remains committed to ensuring effective ongoing business operations and strong customer service,” Haemonetics said.

“These are purposeful actions to streamline the way we work and enable us to better serve our customers, pursue our growth priorities and create an engaging and results-driven culture,” CEO Chris Simon said in prepared remarks.

Back in 2010 Haemonetics said it would cut about 170 workers and close facilities in Phoenix and Chicago as part of the integration of acquisition GlobalMed Technologies. In 2014, another integration – following the $550 million acquisition of Pall – prompted a 320-worker purge and the relocation of its equipment manufacturing from Braintree to a contract facility in Mexico. And in May 2016 the company said it would take a pre-tax charge of $26 million, including $17 million worth of “termination benefits,” as part of another round of layoffs aimed at boosting profitability and growth.

Today Haemonetics also reported fiscal second-quarter results that topped the consensus forecast on Wall Street, posting profits of $20.1 million, or 38¢ per share, on sales of $225.4 million for the three months ended Sept. 1. That amounts to a 1.4% bottom-line gain on sales growth of 2.3% compared with fiscal Q2 2017.

Adjusted to exclude one-time items, earnings per share were 48¢, 7¢ ahead of The Street, where analysts were looking for sales of $219.3 million.

“In the first half of fiscal 2018, we grew revenue 1.4% and adjusted net income 18%. Our turnaround is on track, our strategy is working and we are raising our fiscal 2018 adjusted earnings per share and free cash flow guidance. We are launching a comprehensive complexity reduction initiative to further improve our productivity and allow us to intensify the investments we are making to fuel our growth,” Simon said.

Haemonetics said it now expects to report fiscal 2018 adjusted EPS of $1.65 to $1.75, up from $1.55 to $1.65 previously, on flat revenue growth.

HAE shares closed down -0.6% at $46.83 apiece yesterday.

Filed Under: Blood Management, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Haemonetics

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy